Pancreatic Cancer Research

ResearcherScripps Research InstituteActive in the last 2 years

Gregory P. Botta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9606-4508; OpenAlex author ID A5046764038. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 trial

Papers 7

  1. Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic… Co-author DOI 10.1200/oa-25-00099↗
  2. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  3. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
  4. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.5523↗
  5. Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. Co-author DOI 10.1038/s41525-022-00346-5↗
  6. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. Co-author DOI 10.1172/jci.insight.150453↗
  7. Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. Co-author DOI 10.1158/1541-7786.mcr-11-0399↗

Trials 1

  1. Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Principal investigator NCT06790602↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shumei Kato · 2 shared papers, 2021–2023 · strength 0.34
  2. Razelle Kurzrock · 2 shared papers, 2021–2023 · strength 0.34
  3. Andrew H. Ko · 1 shared paper, 2025 · strength 0.22
  4. Eric Andrew Collisson · 1 shared paper, 2025 · strength 0.22
  5. Mike Cusnir · 1 shared paper, 2025 · strength 0.22
  6. Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.22
  7. Raymond Couric Wadlow · 1 shared paper, 2025 · strength 0.22
  8. Rafael Winograd · 1 shared paper, 2025 · strength 0.22
  9. Erica S. Tsang · 1 shared paper, 2025 · strength 0.22
  10. Kenneth P. Olive · 1 shared paper, 2025 · strength 0.22
  11. Darren S. Sigal · 1 shared paper, 2023 · strength 0.20
  12. Justin A. Shaya · 1 shared paper, 2023 · strength 0.19
  13. Hitendra Patel · 1 shared paper, 2023 · strength 0.19
  14. Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.17
  15. Andreas Seeber · 1 shared paper, 2024 · strength 0.17
  16. Sepideh Gholami · 1 shared paper, 2024 · strength 0.17
  17. Erik B. Faber · 1 shared paper, 2024 · strength 0.17
  18. Heinz‐Josef Lenz · 1 shared paper, 2024 · strength 0.17
  19. Anwaar Saeed · 1 shared paper, 2024 · strength 0.17
  20. Emil Lou · 1 shared paper, 2024 · strength 0.17
  21. Wafik S. El‐Deiry · 1 shared paper, 2024 · strength 0.17
  22. Anthony Frank Shields · 1 shared paper, 2024 · strength 0.17
  23. Gulam Abbas Manji · 1 shared paper, 2024 · strength 0.17
  24. Sreenivasa Rao Chandana · 1 shared paper, 2024 · strength 0.15
  25. Naomi H. Fei · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.